首页 | 本学科首页   官方微博 | 高级检索  
检索        


Prophylactic Oral Amiodarone for the Prevention of Arrhythmias that Begin Early After Revascularization, Valve Replacement, or Repair: PAPABEAR: a randomized controlled trial
Authors:Mitchell L Brent  Exner Derek V  Wyse D George  Connolly Carol J  Prystai Gregory D  Bayes Alexander J  Kidd William T  Kieser Teresa  Burgess John J  Ferland André  MacAdams Charles L  Maitland Andrew
Institution:Libin Cardiovascular Institute of Alberta, Calgary; Calgary Health Region, Calgary, Alberta; and the Department of Cardiac Sciences, University of Calgary, Calgary, Alberta.
Abstract:Context  Atrial tachyarrhythmias after cardiac surgery are associated with adverse outcomes and increased costs. Previous trials of amiodarone prophylaxis, while promising, were relatively small and yielded conflicting results. Objective  To determine whether a brief perioperative course of oral amiodarone is an effective and safe prophylaxis for atrial tachyarrhythmias after cardiac surgery overall and in important subgroups. Design, Setting, and Patients  Double-blind randomized controlled trial of 601 patients listed for nonemergent coronary artery bypass graft (CABG) surgery and/or valve replacement/repair surgery between February 1, 1999, and September 26, 2003, at a tertiary care hospital. The patients were followed up for 1 year. Intervention  Oral amiodarone (10 mg/kg daily) or placebo administered 6 days prior to surgery through 6 days after surgery (13 days). Randomization was stratified for subgroups defined by age, type of surgery, and use of preoperative {beta}-blockers. Main Outcome Measure  Incidence of atrial tachyarrhythmias lasting 5 minutes or longer that prompted therapy by the sixth postoperative day. Results  Atrial tachyarrhythmias occurred in fewer amiodarone patients (48/299; 16.1%) than in placebo patients (89/302; 29.5%) overall (hazard ratio HR], 0.52; 95% confidence interval CI], 0.34-0.69; P<.001); in patients younger than 65 years (19 11.2%] vs 36 21.1%]; HR, 0.51 95% CI, 0.28-0.94]; P = .02); in patients aged 65 years or older (28 21.7%] vs 54 41.2%]; HR, 0.45 95% CI, 0.27-0.75]; P<.001); in patients who had CABG surgery only (22 11.3%] vs 46 23.6%]; HR, 0.45 95% CI, 0.26-0.79]; P = .002); in patients who had valve replacement/repair surgery with or without CABG surgery (25 23.8%] vs 44 44.1%]; HR, 0.51 95% CI, 0.31-0.84; P = .008); in patients who received preoperative {beta}-blocker therapy (27 15.3%] vs 42 25.0%]; HR, 0.58 95% CI, 0.34-0.99]; P = .03); and in patients who did not receive preoperative {beta}-blocker therapy (20 16.3%] vs 48 35.8%]; HR, 0.40 95% CI, 0.22-0.71]; P<.001), respectively. Postoperative sustained ventricular tachyarrhythmias occurred less frequently in amiodarone patients (1/299; 0.3%) than in placebo patients (8/302; 2.6%) (P = .04). Dosage reductions of blinded therapy were more common in amiodarone patients (34/299; 11.4%) than in placebo patients (16/302; 5.3%) (P = .008). There were no differences in serious postoperative complications, in-hospital mortality, or readmission to the hospital within 6 months of discharge or in 1-year mortality. Conclusion  Oral amiodarone prophylaxis of atrial tachyarrhythmias after cardiac surgery is effective and may be safe overall and in important patient subgroups. Clinical Trials Registration  ClinicalTrials.gov Identifier: NCT00251706
Keywords:
本文献已被 PubMed 等数据库收录!
点击此处可从《The Journal of the American Medical Association》浏览原始摘要信息
点击此处可从《The Journal of the American Medical Association》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号